A B S T R A C T The metabolic clearance rate (MCR) of human growth hormone (HGH) was determined by the constant infusion to equilibrium technique utilizing HGH-5I. 22 control subjects had a MCR of 229 ±52 ml/min (mean ±sD). No difference was evident between sexes, or between various age groups. Patients with acromegaly demonstrated normal MCR's. Moreover, acute elevations of plasma growth hormone concentrations in normal subjects did not alter the MCR of HGH. The MCR was relatively constant from day to day and within the day when subjects were evaluated in the supine position. In contrast, the assumption of the upright position was associated with a mean 24% decrease in the MCR.
A B S T R A C T The metabolic clearance rate (MCR) of human growth hormone (HGH) was determined by the constant infusion to equilibrium technique utilizing HGH-5I. 22 control subjects had a MCR of 229 ±52 ml/min (mean ±sD). No difference was evident between sexes, or between various age groups. Patients with acromegaly demonstrated normal MCR's. Moreover, acute elevations of plasma growth hormone concentrations in normal subjects did not alter the MCR of HGH. The MCR was relatively constant from day to day and within the day when subjects were evaluated in the supine position. In contrast, the assumption of the upright position was associated with a mean 24% decrease in the MCR.
These results were contrasted with the MCR of HGH observed in a small number of patients with altered thyroid function or diabetes mellitus. In six patients with hypothyroidism the MCR (131 ±36 ml/min) was significantly decreased (P < 0.001); whereas the MCR in eight patients with hyperthyroidism (240 ±57 ml/min) did not differ from control subjects. The MCR in eight patients with insulin-independent diabetes mellitus (IID) (185 ±41 ml/min) and in eight patients with insulin-dependent diabetes mellitus (IDD) (136 ±31 ml/min) were significantly different from control subjects (P = < 0.05 and P = < 0.001, respectively).
These data were interpreted to indicate that the plasma HGH-removing mechanism(s) is not saturated at physiologic plasma HGH 
INTRODUCTION
Investigators examining the physiologic regulation of plasma human growth hormone (HGH) have been aware that diverse stimuli (1-9) elicit changes in plasma HGH concentrations. Such changes in plasma levels alone, moreover, do not distinguish between the separate contributions of pituitary HGH release and HGH clearance from the plasma, both of which are responsible for a change in plasma concentration.
The plasma disappearance of single intravenous injections of radioisotopically labeled HGH has been analyzed to define the distribution and turnover of HGH in humans (10) (11) (12) . The fractional turnover and production rates of HGH in these studies were derived from calculations which assume first order kinetics and steadystate conditions. Some of the radioisotopic plasma disappearance curves in the literature (10, 11) , however, do not clearly establish whether the plasma disappearance of HGH is linear or nonlinear when plotted semilogarithmically. In the present study, the constant infuThe Journal of Clinical Investigation Volume 48 1969 sion to equilibrium technique of Tait (13) was employed to assess the metabolic clearance (MCR) and production rate (PR) of HGH. This technique has also been utilized in evaluating the metabolism of other polypeptide hormones (14) (15) (16) which have been shown to have a multicompartmental distribution.
METHODS
Preparation of HGH-'I. Highly purified HGH1 was isotopically labeled to specific activities of approximately 150 ,uc/ltg with 'I (Iso/Serv Division, Cambridge Nuclear Corp., Cambridge, Mass.) as described by Greenwood, Hunter, and Glover (17) . 50 p1A of the iodination mixture with 5 til of human plasma was placed on a 5 cm cellulose powder column (Whatman, CF11) prepared in a disposable capillary Pasteur pipette. The cellulose column had been rendered pyrogen free by exposure to dry heat (160'C) for 30 min. The column was first washed with 1.5 ml of sterile 0.1 M veronal buffer, pH 8.6, and the HGH-1lI subsequently eluted with three 0.5-ml washes of 0.1 M veronal buffer containing 20% acetone and 0.25% human albumin (18) . Aliquots of the second and third 0.5-ml acetone elutions were utilized for the infusion studies. The sterility of the HGH-1lI fraction was examined before use by incubation of an aliquot on a blood-agar plate and in thioglycolate broth at 40, 220, and 37'C. Bacterial contamination was not encountered with the labeling and preparatory procedures. The interval between iodination and use of the eluate in human studies was 2-8 days.
Experimental procedure. The subjects of the investigation were evaluated in the supine position in the forenoon after 14-17 hr of fasting. Water intake was permitted up to the start of each study. Each patient received five drops of Lugol's solution by mouth 12 and 2 hr before study. A slow intravenous 0.85% NaCl infusion was begun through each of two indwelling plastic cannulae placed in opposite antecubital veins. 60 min were then allowed to elapse before initiating the studies. Blood samples were withdrawn through one cannula and HGH-'I, in 1% human serum albumin and 0.85% NaCl was infused via a constant infusion pump through the other. After injection of approximately 5 ,uc as a priming dose, 15-25 uc of the diluted HGH-'I was infused at a constant rate of 1 ml/min over 2.5-3 hr.
Heparinized blood specimens were obtained before and every 15 min until the termination of the infusion. The plasma was immediately separated for analysis of immunoprecipitable HGH-'2I and an aliquot was frozen for subsequent determination of endogenous HGH concentration.
Measurement of HGH-'5I and endogenous plasma HGH concentration. The plasma samples were analyzed for immunoprecipitable HGH-'I content by a double-antibody precipitation method immediately after each study (19) . Duplicate 1 ml aliquots of plasma in 0.1 ml of 0.1 M ethylenediaminetetraacetic acid (EDTA) were incubated with 0.2 ml of guinea pig anti-HGH serum (final concentration 1: 8500) for 48 hr at 4°C. Sunbsequently, 0.1 ml of nonimmune guinea pig plasma and 0.1 ml of rabbit anti-guinea pig gamma globulin (Hyland Laboratories) (final concentration 1:1500) were added and the mixture was incubated for an additional 24 hr at 4°C. All dilutions were made with 0.1 M Veronal buffer, pH 8.6 . After centrifugation, the supernate was decanted and the precipitate washed twice with I Gift from the National Pituitary Agency through Dr.
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0.5 ml of Veronal buffer. The radioactivity counts in the precipitate were determined in a well-type scintillation counter to a statistical accuracy of greater than 98%.
Eluates from the cellulose column utilized in the infusion studies were subjected to hydrodynamic flow chromatoelectrophoresis on Whatman 3MC chromatography paper (20) . The eluates contained no free 'I and less than 15% 'I-labeled material that migrated beyond the chromatogram origin. In a series of control studies, fractions of column eluates were incubated with guinea pig anti-HGH sera at final concentrations of 1:8500 for 48 hr. Chromatoelectrophoresis of these mixtures revealed that in excess of 95% of the undamaged HGH-';I migrated beyond the chromatogram origin, predominantly as antibody-bound HGH-'I. Aliquots of the eluates in 0.5 ml of human plasma were also examined by the double-antibody precipitation technique. 90% or more of the undamaged HGH-';I, as assessed by paper chromatography, was precipitated in the doubleantibody procedure utilized in the studies. The slight discrepancy between the per cent of undamaged HGH-wII and immunoprecipitable HGH-'lI as assessed by paper chromatography and double-antibody precipitation techniques, respectively, may be due to "incubation damage" to the isotopically labeled HGH (20) , incomplete precipitation by the rabbit anti-guinea pig antisera, or the inability of paper chromatography to totally distinguish "radiation damaged" (21) immunononreactive from unmodified immunoreactive HGH. A fivefold increase in the concentration of guinea pig anti-HGH and or rabbit anti-guinea pig sera did not alter this discrepancy. Further, the addition of the rabbit antiguinea pig antibody to the incubation mixture at 24 rather than at 48 hr incubation did not enhance the immunoprecipitability of the HGH tracer. When unlabeled HGH in final concentrations up to 200 mpug/ml were added to the HGH-5I tracer in human plasma in vitro, the immunoprecipitability of the tracer was not significantly altered.
The immunoprecipitability of the HGH-12I in each infusion mixture was determined in 0.5 ml of the infusate added to 0.5 ml of the patient's plasma obtained before the experiment. 75-85% of the radioactivity counts in the infusate were immunoprecipitable. Immunoprecipitability in aliquots of the infusion mixture obtained at various times throughout the infusion period did not vary. By radioautography of chromatograms of the column eluates or infusates, no aggregation of HGH-1"I was observed (22) .
The endogenous plasma HGH concentration was measured in duplicate by a modification (23) of the dextran-coated charcoal immunoassay method of Herbert (24), using HGH-131I as the tracer. Neither the 'I content or the trace amounts of HGH-'I in the plasma interfered with the "'I-counting or immunoassay procedure.
Calculations. The plasma immunoprecipitable HGH-wlI concentrations reached equilibrium by 60 min after the start of the constant infusion. The plasma metabolic clearance rate (MCR) was determined from four or more consecutive samples in which the immunoprecipitable HGH-9I and the endogenous plasma HGH concentrations were constant.
The plasma metabolic clearance rate (MCR) and the production rate (PR) were calculated according to the general formula of Tait (13):
where r is the rate of the infusion of HGH-'I in cpm/min and x'c is the plasma HGH-'I level in cpm/ml after equilibrium has been reached. Only the immunoprecipitable HGH-w'I in the infusion solution was used to calculate the (25) . The significance of the differences in the means of the MCR, PR, and plasma endogenous HGH concentrations in each of the study groups were analyzed by Student's t test.
Subjects and patients. Adults were evaluated after informed consent. The results of five studies are not included because plasma equilibrium of either immunoprecipitable HGH-'I or endogenous plasma HGH, or both, was not achieved. The control group consisted of 13 males and 9 females, aged 17-75 yr. Four of the patients who served as controls had recently recovered from bacterial pneumonia, one had recovered from saphenous vein thrombophlebitis, and 16 were normal nonhospitalized volunteers. 16 patients had diabetes mellitus, eight required insulin, and eight were managed by diet and oral hypoglycemic agents. Two insulinrequiring and two insulin-independent patients with diabetes mellitus were hospitalized for diabetic control at the time of study. The insulin-independent patients with diabetes mellitus consisted of five women and three men, aged 52-63 yr. The insulin-dependent patients with diabetes mellitus consisted of eight men, aged 29- Control studies. Two normal subjects (Nos. 8 and 17) who underwent studies after the usual protocol were also evaluated during the constant infusion of unlabeled HGH.
After the 60 mmn rest period, a 50 ,sg priming dose of HGH was injected intravenously followed by a constant infusion of HGH at 2.9 and 7.7 Aeg/min. Heparinized blood samples were withdrawn at the usual times over 3 hr. The plasma obtained and an aliquot of the infusion was frozen until analyzed for the concentration of HGH by radioimmunoassay.
Three normal subjects (Nos. 17, 21, and 22) underwent studies in the supine position after the usual protocol except that unlabeled HGH was infused at a constant rate (12, 10, and 10 /hg/min, respectively) beginning 120 min after the initiation of the HGH-'I infusion and continuing for an additional 90 min.
Four subjects (Nos. 12-15) underwent studies in the supine and erect positions starting at 8:00 a.m. After 135 min of the constant HGH-wlI infusion and plasma sampling in the supine position, the subjects stood erect and plasma samples were collected every 15 min for 60 min while the infusion was maintained. The supine study was repeated 36 hr later (8 :00 p.m.) in the same subjects.
RESULTS
The MCR of HGH after the infusion of unlabeled HGH in patients 8 and 17 were calculated to be 169 and 328 (Fig. 1) . These four subjects were also evaluated in prone and erect positions beginning at 8:00 a.m. Standing erect was associated with a mean 24% decrease in the MCR. The MCR's and PR's for the constant infusion studies were derived from the data listed in Tables III and IV (26) . The 22 control patients had a mean MCR of 229 ±52 (mean -+SD) ml/min and a mean PR of 347 ±173 mng/min. The mean plasma HGH concentration was 1.5 ±0.7 rnmg/ml. No difference in MCR, PR, or endogenous plasma HGH was observed between the sexes. The blood glucose 'concentration was normal in all patients except in the diabetic patient groups. The blood glucose did not vary more than 5% during the -study in the control or patient study groups.
The six hypothyroid patients had a mean MCR and PR of 131 ±36 ml/min and 160 ±69 nmug/min, respectively (Table III and Fig. 2 ). The mean MCR and PR observed in the hypothyroid patients were significantly decreased when compared to the control subjects (P < 0.001 and < 0.02, respectively). The mean plasma HGH concentration of 1.3 ±0.6 nmg/ml was not significantly different from the control subjects. The eight hyperthyroid patients had a mean MCR of 240 ± 57 ml/min which was not different from the control value (Table  III and Fig. 2 (Table IV and Fig. 2 ) had a mean MCR and PR of 185 ±41 ml/min and 245 ±100 m,*g/min, respectively. The mean basal plasma HGH concentration was 1.3 ±0.5 msjg/ml. The mean MCR was significantly lower than in control subjects (P < 0.05). The PR and endogenous plasma HGH concentrations were not significantly different from the control subjects. The mean MCR of 136 ±31 ml/min in the eight patients with insulin-dependent diabetes mellitus (Table IV and Fig. 2) was significantly decreased when compared to the control subjects (P < 0.001), and patients with insulinindependent diabetes mellitus (P < 0.02). The mean basal endogenous plasma HGH concentration of 2.6 ±0.8 mig/ml was significantly increased when compared to the control value (P < 0.01) and patients with insulin-independent diabetes mellitus (P < 0.01). The mean PR of 363 ±153 msg/ml was not significantly different from the control value. There was no correlation between the fasting blood glucose concentration and the endogenous plasma HGH concentration or the MCR of HGH-'I. Correction of the MCR and PR of HGH for differences in body surface area (Tables III and IV) did not alter the relative differences determined between various patient groups and control subjects.
DISCUSSION
The constant infusion technique was employed for all studies after it was established that under the conditions of the experimental protocol, relatively steady-state concentrations of both infused radioisotopically labeled hormone and endogenous unlabeled hormone could be attained. The similarity of the MCR's of HGH (Table I) derived from data obtained during the constant infusion of unlabeled HGH (when allowances were made for endogenous production) to that obtained during the infusion of radioisotopically labeled HGH supports the validity of the tracer in estimating the MCR of HGH.
In the control group as a whole, there were no significant differences in the MCR of HGH between sexes, nor between subjects less than or greater than 45 yr of age. Constancy of the MCR both within the day (Fig. 1) and from day to day was observed (patients 8 and 17, Table I , and patient 37, Table III ). The only maneuver studied which resulted in a change in MCR was the assumption of an upright position. Although the MCR of HGH is considerably less than hepatic blood flow (27) , the reduction in the latter, upon assumption of the upright position (28) , is comparable to the reduction in MCR which was observed. Whether these observations are related, remains to be elucidated.
The measurements of the MCR before and after acute elevation of plasma HGH to a new steady-state level, revealed no alterations in the MCR. Further, the MCR of HGH in patients with acromegaly and chronic elevations of plasma HGH concentrations did not differ front control subjects. This dissociation of MCR and plasma HGH concentration implies that the plasma HGHremoving mechanisms are not saturated at physiologic plasma HGH levels. As suggested by Stern, Farquhar, Silvers, and Reaven (15) , this is a desirable feature of a control system in which rapid adjustments of plasma concentrations are necessary. Similar to the current experiments, elevated plasma concentrations of other polypeptide hormones, insulin (15) , luteinizing hormone (LH) (14) , follicle-stimulating hormone (FSH) (16) , and human placental prolactin (HPL) (29) do not appear to alter their respective MCR's from the plasma.
The mean daily PR of HGH calculated from the equilibrium PR in the supine control subjects was 0.5 mg. This is in close agreement with the prediction of Glick, Roth, Yalow, and Berson (3) . Although this amount approximates the mean daily replacement requirements for linear growth in hypopituitary dwarfs (30) Tables III and IV , that either the steady state attained or the reproducibility of the assay was more satisfactory for the determination of the concentration of the labeled tracer than it was for the measurement of endogenous HGH plasma concentration. In our experiments, these alternatives were not distinguished. Using logarithmic transformations of the two variables used to calculate each PR (25) yields 95% confidence limits of the PR which are as large as the PR's determined for most of the control subjects. Accordingly, interpretation of the significance of the differences in the PR's observed within and between various groups of patients must remain uncertain.
The determination of the MCR of HGH as a component of the physiologic regulation of plasma HGH contration may clarify the mechanism of alterations in plasma HGH responses to provocative stimuli. Impoverished plasma HGH responses to insulin-induced hypoglycemia have been reported in patients with hypothyroidism (35, 36) and hyperthyroidism (37 results of the present studies suggest that if the blunted plasma HGH responses in patients with hyperthyroidism are encountered, they cannot be explained on the basis of increased peripheral clearance of the hormone. Recent observations, moreover, indicate that plasma HGH responses to hypoglycemia are normal in patients with hyperthyroidism (38) . In patients with hypothyroidism, the reduced MCR of HGH indicates that abnormalities in the growth hormone-releasing mechanism account for the diminished plasma HGH responses to insulin-induced hypoglycemia. In accord with an abnormality of the growth hormone-releasing mechanism, Lewis, Cheever, and VanderLaan (39) with a bioassay, and Daughaday, Peake, Birge, and Mariz (40) with an immunoassay, determined that hypothyroidism diminishes the content of HGH in the rat hypophysis.
The explanation for the reduction in MCR in both diabetic groups is not apparent. Clinical indications of dehydration, alterations in circulation, or hepatic, renal, or muscle disease were sought but not found. In contrast to the findings reported, Boucher (12) found that the MCR in patients with insulin-dependent diabetes mellitus was normal. However, because the plasma decay curve of injected radioisotopically labeled HGH was treated as a single exponential function, the results cannot be compared.
Despite the markedly low mean MCR in the insulindependent diabetic group, the mean PR was normal because of the higher mean plasma HGH concentration. This elevation is at variance with the normal fasting HGH levels in patients with diabetes mellitus recorded by several investigators (3, (41) (42) (43) . In most of the reports, however, the heterogeneity of the diabetic and contrast groups and the circumstances of the study which might affect the plasma HGH concentration are not defined (8, 9, 32, 33, 44 46 ). In the present study, both control subjects and patients were exposed to similar stimuli under carefully controlled conditions. Secondly, relatively steady-state concentrations of plasma HGH were a requisite in this study so (47) , and decreased responses to arginine in maturity onset diabetes (48) normal plasma HGH responses to various provocative stimuli have been generally observed (3, 4143, [49] [50] [51] . The results of our studies emphasize, however, that plasma HGH levels alone, do not permit distinction between abnormalities in pituitary release of the hormone and its rate of clearance from plasma. Further studies may help clarify the mechanism and significance of the reduced MCR of HGH observed in patients with diabetes mellitus.
